213 related articles for article (PubMed ID: 24342286)
1. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.
Rossi G; Graziano P; Leone A; Migaldi M; Califano R
Semin Diagn Pathol; 2013 Nov; 30(4):298-312. PubMed ID: 24342286
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
4. Genetics and biomarkers in personalisation of lung cancer treatment.
Rosell R; Bivona TG; Karachaliou N
Lancet; 2013 Aug; 382(9893):720-31. PubMed ID: 23972815
[TBL] [Abstract][Full Text] [Related]
5. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.
Cooper WA; O'toole S; Boyer M; Horvath L; Mahar A
Pathology; 2011 Feb; 43(2):103-15. PubMed ID: 21233671
[TBL] [Abstract][Full Text] [Related]
6. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
[TBL] [Abstract][Full Text] [Related]
7. Personalized therapy of lung cancer.
Thomas R; Wolf J
Onkologie; 2012; 35 Suppl 1():14-9. PubMed ID: 22286583
[TBL] [Abstract][Full Text] [Related]
8. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
9. [Molecular pathology of lung cancer in routine diagnostic practice: 2017 update].
Matěj R; Rohan Z; Němejcová K; Dundr P
Cesk Patol; 2017; 53(4):159-166. PubMed ID: 29227119
[TBL] [Abstract][Full Text] [Related]
10. Tissue sampling in lung cancer: a review in light of the MERIT experience.
Reck M; Hermes A; Tan EH; Felip E; Klughammer B; Baselga J
Lung Cancer; 2011 Oct; 74(1):1-6. PubMed ID: 21658788
[TBL] [Abstract][Full Text] [Related]
11. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].
Warth A
Pathologe; 2015 Nov; 36 Suppl 2():194-200. PubMed ID: 26391251
[TBL] [Abstract][Full Text] [Related]
13. MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.
Reis H; Metzenmacher M; Goetz M; Savvidou N; Darwiche K; Aigner C; Herold T; Eberhardt WE; Skiba C; Hense J; Virchow I; Westerwick D; Bogner S; Ting S; Kasper S; Stuschke M; Nensa F; Herrmann K; Hager T; Schmid KW; Schuler M; Wiesweg M
Clin Lung Cancer; 2018 Jul; 19(4):e441-e463. PubMed ID: 29631966
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
[TBL] [Abstract][Full Text] [Related]
15. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Reungwetwattana T; Weroha SJ; Molina JR
Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
[TBL] [Abstract][Full Text] [Related]
17. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
18. Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer.
Kulesza P; Ramchandran K; Patel JD
Am J Clin Pathol; 2011 Aug; 136(2):228-38. PubMed ID: 21757595
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.
Hosokawa S; Toyooka S; Fujiwara Y; Tokumo M; Soh J; Takigawa N; Hotta K; Yoshino T; Date H; Tanimoto M; Kiura K
Lung Cancer; 2009 Oct; 66(1):107-13. PubMed ID: 19185949
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy for NSCLC with driver mutations.
Minuti G; D'Incecco A; Cappuzzo F
Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
